HCPCS Level II code A9527 designates Iodine I-125 sodium iodide solution for therapeutic use, billed per millicurie. This code captures the radioisotope component used in targeted radiation treatments, frequently employed in oncology and select thyroid therapies. Nationally, accurate coding for radiopharmaceuticals like A9527 is important for consistent claims processing, inventory management, and cost reporting for facilities administering radioactive therapies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the clinical context of I-125 therapeutic use, the typical sites of service where claims for A9527 arise, and the payer landscape addressed. The publication outlines common billing considerations tied to radiopharmaceuticals, benchmark and reimbursement framing where available, and relevant policy or coverage touchpoints that affect national utilization and billing practices.

This summary provides operational clarity for coding professionals, revenue cycle staff, and facility managers seeking a national-level reference on A9527, focusing on billing characterization, payer coverage scope, and clinical service context. Data not available in the input is noted where applicable.